ANI Pharmaceuticals, Inc.
ANIP
$76.53
$0.430.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.78% | 48.87% | 38.68% | 30.26% | 26.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.78% | 48.87% | 38.68% | 30.26% | 26.20% |
| Cost of Revenue | 36.41% | 47.44% | 43.42% | 42.04% | 37.85% |
| Gross Profit | 48.85% | 49.80% | 35.76% | 23.26% | 19.28% |
| SG&A Expenses | 36.37% | 41.24% | 58.39% | 49.58% | 43.19% |
| Depreciation & Amortization | 34.97% | 51.52% | 41.38% | 27.03% | 13.28% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.69% | 45.49% | 48.45% | 40.64% | 35.85% |
| Operating Income | 309.64% | 117.52% | -54.24% | -61.47% | -58.98% |
| Income Before Tax | 531.26% | 773.73% | -141.54% | -164.03% | -211.78% |
| Income Tax Expenses | 573.01% | 2,522.09% | -153.42% | -186.88% | -437.60% |
| Earnings from Continuing Operations | 522.94% | 672.15% | -137.80% | -159.21% | -198.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 522.94% | 672.15% | -137.80% | -159.21% | -198.63% |
| EBIT | 309.64% | 117.52% | -54.24% | -61.47% | -58.98% |
| EBITDA | 98.35% | 71.41% | -2.78% | -14.39% | -19.46% |
| EPS Basic | 439.90% | 489.11% | -158.09% | -171.36% | -220.85% |
| Normalized Basic EPS | 5,742.86% | 438.42% | -93.73% | -107.02% | -104.59% |
| EPS Diluted | 422.18% | 458.77% | -160.92% | -173.56% | -224.65% |
| Normalized Diluted EPS | 4,769.81% | 435.71% | -95.25% | -107.83% | -105.38% |
| Average Basic Shares Outstanding | 3.79% | 2.78% | 2.60% | 4.16% | 7.37% |
| Average Diluted Shares Outstanding | 7.25% | 4.56% | 2.74% | 3.43% | 6.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.17% | 1.17% | -3.65% | -2.69% | -2.01% |